Pharm Res (2018) 35:95 https://doi.org/10.1007/s11095-018-2365-x RESEARCH PAPER Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer 1 2 1 Tanaya Vaidya & Robert M. Straubinger & Sihem Ait-Oudhia Received: 7 September 2017 /Accepted: 10 February 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 ABSTRACT HER2 positive breast cancer cells and deliver chemotherapy, Purpose Trastuzumab combined with Doxorubicin (DOX) and have the potential to improve clinical outcomes. demonstrates significant clinical activity in human epidermal . . growth factor receptor-2 (HER2)-positive breast cancer (BC). KEY WORDS anti-CD3 HER2-positive breast cancer . . However, emergence of treatment resistance and trastuzumab immunoliposomes trastuzumab doxorubicin associated cardiotoxicity remain clinical challenges. In an ef- fort to improve patient outcome, we have developed and eval- uated novel tri-functional immunoliposomes (TFIL) that tar- ABBREVIATIONS get HER2-receptors on BC cells and CD3-receptors on T- BC Breast Cancer lymphocytes, and deliver DOX. CD3 Cluster of Differentiation Receptor Type 3 Methods Trastuzumab (anti-HER2) and OKT-3 (anti-CD3) CTLs Cytotoxic T Lymphocytes antibodies were conjugated to liposomes using a micelle- DOX Doxorubicin transfer method. Cytotoxicity of targeted immunoliposomes HER2 Human Epidermal Growth Factor Receptor Type 2 loaded with DOX was examined in vitro on
Pharmaceutical Research – Springer Journals
Published: Mar 13, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud